SABS insider transaction filings
SAB Biotherapeutics, Inc. — 27 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-26. Screen SABS transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-26 | 4 | Kropotova Alexandra — CHIEF MEDICAL OFFICER | Tax withholding (F): 988 | EDGAR |
| 2026-03-25 | 4 | Kropotova Alexandra — CHIEF MEDICAL OFFICER | Tax withholding (F): 988 | EDGAR |
| 2026-02-05 | 4 | Sullivan Eddie Joe — PRESIDENT, Director | Grant/award (A): 3,000,000 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | Bausch Christoph Lawrence — CHIEF OPERATING OFFICER | Grant/award (A): 1,800,000 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | To Lucy — See Remarks | Grant/award (A): 2,400,000 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | Kropotova Alexandra — CHIEF MEDICAL OFFICER | Grant/award (A): 2,400,000 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | Reich Samuel J — CEO, Director | Grant/award (A): 4,800,000 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Jain Rita — Director | Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | ZACCARDELLI DAVID — Director | Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Polvino William James — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Ellias Helen K. — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Giberson Scott — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Link David — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Lucera Erick — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | SKYLER JAY S — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-12-12 | 4 | Kropotova Alexandra — CHIEF MEDICAL OFFICER | Tax withholding (F): 988 | EDGAR |
| 2025-10-01 | 4 | Moin Andrew — Director | Option exercise (M): 1,740,000 @ $1.75 · Option exercise (M): 17,400 (derivative) | EDGAR |
| 2025-10-01 | 4 | Sessa Capital (Master), L.P. — Director Sessa Capital GP, LLC — Director Sessa Capital IM, L.P. — Director Sessa Capital IM GP, LLC — Director Petry John — Director | Option exercise (M): 1,740,000 @ $1.75 · Option exercise (M): 17,400 (derivative) | EDGAR |
| 2025-09-22 | 4 | Kropotova Alexandra — CHIEF MEDICAL OFFICER | Tax withholding (F): 1,977 | EDGAR |
| 2025-08-28 | 4 | To Lucy — See Remarks | Grant/award (A): 1,200,000 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Bausch Christoph Lawrence — CHIEF OPERATING OFFICER | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Sullivan Eddie Joe — PRESIDENT, Director | Grant/award (A): 3,000,000 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Kropotova Alexandra — CHIEF MEDICAL OFFICER | Grant/award (A): 2,400,000 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Reich Samuel J — CEO & EXECUTIVE CHAIRMAN, Director | Grant/award (A): 4,800,000 (derivative) @ $0 | EDGAR |
| 2025-07-24 | 4 | Moin Andrew — Director | Grant/award (A): 228,500 (derivative) · Grant/award (A): 228,500 (derivative) · Grant/award (A): 114,250 (derivative) | EDGAR |
| 2025-07-24 | 4 | Sessa Capital (Master), L.P. — Director Sessa Capital GP, LLC — Director Sessa Capital IM, L.P. — Director Sessa Capital IM GP, LLC — Director Petry John — Director | Grant/award (A): 228,500 (derivative) · Grant/award (A): 228,500 (derivative) · Grant/award (A): 114,250 (derivative) | EDGAR |
| 2025-04-01 | 4 | Kropotova Alexandra — CHIEF MEDICAL OFFICER | Tax withholding (F): 1,179 | EDGAR |
Recent 8-K events — SAB Biotherapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-07 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-22 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-19 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-10 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-07 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-29 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-09-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SABS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →